Financial Performance - Revenue from continuing operations for the six months ended September 30 was HKD 810,002 thousand, an increase of 13.3% compared to HKD 714,918 thousand in the previous period[6]. - Gross profit for the same period was HKD 351,471 thousand, reflecting a growth of 16.7% from HKD 301,079 thousand[6]. - Adjusted EBITDA from continuing operations reached HKD 272,185 thousand, up 24.8% from HKD 218,120 thousand[6]. - The company reported a net profit attributable to equity holders of HKD 140,290 thousand, down 8.9% from HKD 154,040 thousand[6]. - The gross profit margin improved to 43.4% from 42.1% in the previous period[6]. - Profit from continuing operations for the same period rose significantly by 44.2% to HKD 140.3 million, driven by strong performance in both public and private sectors[24]. - The group reported a consolidated profit before tax of HKD 175,377 thousand for the six months ended September 30, 2024, compared to HKD 118,860 thousand in the same period of 2023, indicating a significant increase of approximately 47.5%[174]. - The company reported a profit attributable to equity holders of HKD 140,290,000 for the six months ended September 30, 2024, compared to HKD 154,040,000 in the previous year[189]. Assets and Liabilities - Total assets as of September 30, 2024, amounted to HKD 3,606,697 thousand, a 3.4% increase from HKD 3,486,854 thousand[6]. - Total liabilities increased by 5.5% to HKD 1,150,942 thousand from HKD 1,090,494 thousand[6]. - The net debt-to-equity ratio decreased significantly from 12.2% at the end of the previous fiscal year to 5.6%, indicating improved financial stability[24]. - Cash reserves remained resilient, totaling HKD 515.9 million at the end of the reporting period, showcasing the company's operational discipline[24]. - The company’s equity attributable to equity holders increased to HKD 2,431,536 thousand from HKD 2,372,141 thousand, reflecting a growth of 2.5%[150]. Market and Product Development - The company aims to expand into new areas through innovative solutions and strategic R&D investments[11]. - The company is strategically focusing on expanding its product portfolio, particularly in specialty drugs and biosimilars, to capture fast-growing market segments[16]. - The cardiovascular product line, including Eplerenone, Lisinopril, and Atenolol, achieved significant sales growth due to successful public procurement, contributing to the overall strong performance of the group[28]. - The group launched new products such as Sildenafil Tablet 20mg, Cyanocobalamin Tablet 50mcg, and Amlodipine Oral Solution, and received registration approval for 15 additional new products, enhancing its ability to meet diverse healthcare needs[29]. - As of September 30, 2024, the product pipeline expanded to 193 products, with 65 approved, 14 awaiting approval, and 58 in stability preparation or research stages, demonstrating the group's commitment to long-term growth[30]. Strategic Initiatives - The company is actively exploring partnerships with local and overseas R&D institutions to develop innovative drug manufacturing technologies[16]. - The group plans to collaborate with SDK Therapeutics Inc. for Phase 3 clinical trials in the U.S. and EU, aiming to improve treatment standards for acute promyelocytic leukemia by transitioning from intravenous to oral administration[37]. - The group signed multiple exclusive licensing agreements to enhance its product portfolio in cardiovascular health, diabetes management, and allergy treatment, including a new anticoagulant for thrombus prevention and treatment[35]. Corporate Governance and Compliance - The company has complied with all applicable laws and regulations during the reporting period, with no significant regulatory non-compliance issues reported[96]. - The audit committee, consisting of three independent non-executive directors, oversees the company's financial reporting and internal control systems[103]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[99]. Shareholder Information - The company declared an interim dividend of HKD 0.035 per share, totaling approximately HKD 70 million, compared to HKD 0.025 per share for the same period last year[107]. - Major shareholders include Mr. Chan with a beneficial interest in 1,191,638,000 shares, representing 59.58% of the company[120]. - The stock option plan allows for a maximum of 138,000,000 shares to be issued, equivalent to approximately 6.90% of the issued shares as of the report date[126]. Economic Outlook - The Hong Kong economy is expected to grow by 1.8% year-on-year in Q3 2024, although growth has slowed down due to geopolitical tensions and weak private consumption[42]. - The non-patent drug market is projected to grow due to increased government healthcare investments and the introduction of chronic disease management programs[42].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 截至二零二四年九月三十日止六個月的 中期業績公告 | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | ...

財務摘要 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 二零二一 財年 二零二二 財年 二零二三 財年 二零二四 財年(1) 二零二零 財年 資產淨值 （千港元） 於二零二四年 (3) 來自持續經營業務的經調整EBITDA率根據來自持續經營業務的經調整EBITDA除以來自持續經營業務的收益再乘以100%計算得出。 各位股東： 致力卓越營運 展望未來，儘管我們預期在疫情後將會逐步復甦，但我們深知目前的 地緣政治緊張局勢及動盪對當前的經濟帶來不明朗因素。雖然我們意 識到市場上的種種逆境，但對經濟長期韌性及非專利藥市場以至更廣 泛的醫療保健行業的增長潛力仍然抱持樂觀態度。我們致力在這個日 新月異的時局中培養我們的企業適應力及靈活性，為可持續發展奠下 堅實的基礎。 最後，本人謹代表董事會向我們的僱員、合作夥伴和股東致以衷心的 感謝。你們堅定不移的支持和貢獻，為我們致力提供可及、優質的醫 療解決方案，並為所有持份者創造可持續價值的旅程帶來關鍵助力。 二零二四年六月二十日 | --- | --- | --- | |------- ...

Financial Performance - For the fiscal year ending March 31, 2024, revenue from continuing operations was approximately HKD 1,467.8 million, an increase of about 15.8% compared to HKD 1,267.6 million in the same period of 2023[1]. - Operating profit from continuing operations for the same fiscal year was approximately HKD 333.1 million, up about 17.2% from the adjusted operating profit of HKD 284.3 million in 2023[1]. - Profit for the year was approximately HKD 290.8 million, representing a 14.4% increase from the adjusted profit of HKD 254.1 million in the previous year[1]. - The company's total comprehensive income attributable to equity holders from continuing operations for the year ended March 31, 2024, was HKD 193,815, a decrease of 38.6% compared to HKD 315,570 for the same period in 2023[23]. - The reported segment revenue for the year ended March 31, 2024, was HKD 1,467,814,000, representing an increase of 15.7% compared to HKD 1,267,868,000 for the previous year[64]. - The adjusted EBITDA for the reporting segments was HKD 453,079,000 for the year ended March 31, 2024, compared to HKD 444,173,000 for the previous year, reflecting a growth of 2%[64]. - The company reported a profit attributable to equity holders of HKD 210,236,000 from continuing operations for the year ended March 31, 2024, compared to HKD 207,513,000 for the previous year[70]. - The company’s total comprehensive income for the year ended March 31, 2024, was HKD 254,583,000, compared to HKD 250,345,000 for the previous year, showing a modest increase[65]. - The company’s effective tax rate for the year was maintained at 16.5%, consistent with the previous year[68]. Dividends - The board proposed a final dividend of HKD 0.03 per share, totaling approximately HKD 60.0 million, compared to a final dividend of HKD 0.0238 per share in 2023[1]. - The proposed final dividend per share is HKD 3.00 for the year ended March 31, 2024, compared to HKD 2.38 for the previous year, indicating an increase of 26.1%[74]. - The company distributed a special dividend of 492,259,244 shares of Jianbei Miao Miao, equivalent to approximately HKD 29.52 per share based on the closing price of HKD 1.16 on August 24, 2023[77]. Assets and Liabilities - Non-current assets totaled HKD 2,522.4 million, a decrease from HKD 3,623.1 million in the previous year[5]. - Current assets decreased to HKD 591.6 million from HKD 1,100.98 million in the previous year[5]. - Total equity decreased to HKD 2,396.4 million from HKD 3,256.5 million in the previous year[6]. - Cash and cash equivalents were HKD 411.9 million, down from HKD 1,036.4 million in the previous year[5]. - Non-current liabilities decreased significantly to HKD 717,651 as of March 31, 2024, from HKD 1,467,542 in 2023, a reduction of 51.1%[26]. - The net asset value of the company was HKD 2,396,360 as of March 31, 2024, down from HKD 3,256,522 in 2023, indicating a decline of 26.4%[26]. - The company’s total liabilities decreased to HKD 1,467,542 in 2024 from HKD 2,234,000 in 2023, indicating a reduction of 34.4%[26]. Operations and Market Presence - The company is primarily engaged in the development, production, marketing, and sale of non-patent drugs, with operations mainly in Hong Kong[7]. - The brand healthcare segment's performance has been classified as discontinued operations for the fiscal year ending March 31, 2024[4]. - The company has ceased operations in the brand medical healthcare business, classifying it as a discontinued operation[85]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[67]. - The company is optimistic about future growth, focusing on expanding its product portfolio and enhancing R&D capabilities[94]. - The company is developing an innovative e-business platform tailored for private clinics, which has received positive feedback and shows promising adoption rates[124]. - The company has expanded distribution agreements in selected Southeast Asian countries, including a signed agreement with Malaysia, and is considering clinical trials in the UK, Netherlands, and the US[179]. Research and Development - Research and development costs, excluding capitalized development costs, were HKD 6,450 for the year ended March 31, 2024, compared to HKD 1,166 in 2023, showing a significant increase[44]. - The R&D pipeline includes 185 products at various development stages, with 64 products already registered and 12 submitted for approval[145]. - The company successfully submitted 12 products for approval, enhancing its product pipeline and future market offerings[94]. - The company obtained exclusive rights to six effective specialty drugs across various fields, including gastrointestinal diseases and oncology, enhancing its product portfolio and driving continuous growth[123]. Employee and Operational Costs - Employee costs rose by HKD 42.6 million or 18.0%, reflecting the need for increased production to meet product demand[170]. - The group employed 1,723 employees as of March 31, 2024, compared to 1,484 employees as of March 31, 2023, indicating a strategic increase in workforce[189]. - The group provides various employee benefits, including annual leave, mandatory provident fund, group medical insurance, and life insurance[189]. - The company maintains a strong focus on employee recruitment, development, and retention, offering competitive compensation and training programs[161]. Market Trends and Demand - The demand for basic and specialty pharmaceuticals increased due to the recovery of social activities post-pandemic[105]. - The increase in flu cases, particularly among children and the elderly, has driven demand for cold and flu medications, resulting in growth in both public and private sector businesses during the reporting period[132]. - The aging population with complex health needs is driving the demand for chronic disease management medications, aligning with the value proposition of the non-patent drug market[184]. - The economic recovery in Hong Kong post-COVID-19 has led to a significant increase in inbound tourism and consumer spending, contributing to strong performance since Q1 2023[128]. Strategic Initiatives - The company’s strategic execution has resulted in substantial achievements and effective cost management[122]. - The collaboration with Fosun Kite Biotechnology for the CAR-T cell therapy Yescarta aims to enhance treatment options for specific types of lymphoma[151]. - The initial pilot phase of the medical e-business system has yielded positive results, reflected in good user feedback and excellent adoption rates[181]. - The platform provides unparalleled convenience for medical professionals and key customers, facilitating easy access to the product range and streamlining the ordering process[182].

智通财经APP讯，雅各臣科研制药(02633)发布公告，于2024年2月19日，该公司与配售代理订立配售协议，公司委任配售代理按尽力基准且须满足配售协议的先决条件，按每股配售股份0.60港元的价格向不少于六名独立承配人(或公司与配售代理以书面协定的承配人数目)配售合共6600万股配售股份，每股配售股份的配售价为0.60港元，较2月19日收市价每股0.61港元折让约1.64%，假设配售股份获悉数配售，则最高数目的6600万股配售股份占公司经发行最高数目的配售股份扩大后已发行股本约3.30%。 假设配售股份获悉数分配，则配售所得款项总额将约为3960万港元，所得款项净额预期将约为3880万港元。公司拟动用该等所得款项净额，透过增强生产及包装流程自动化以扩大其生产能力。所得款项净额将主要用作翻新集团生产设施以及购置机器及设备的开支。 ...

Pharma Corporation 003 (3) 經調整EBITDA率根據經調整EBITDA除以來自持續經營業務的收益再乘以100%計算得出。 004 本集團大力投資其商業基礎設施，並管理自身的倉儲、物流、監管、質控以及銷售及營銷業務。我們以SAP系統支援的倉儲綜合設施位於香港的 交通樞紐，有助確保以較高供應鏈效率及靈活度為客戶提供物流解決方案。 005 業務回顧 我們堅定不移地推進業務策略與可持續發展的結合，在環境、社會及 管治舉措方面取得顯著進展。我們的首要重點仍是加快實施可持續發 展策略，即雅各臣的「五恆發展」，當中涵蓋五大核心支柱：「企業管治 責任」、「產品責任」、「社會參與」、「環境管理」及「對僱員的承諾」。我 們的環保承諾為該框架的重要組成部分，且我們正致力達致我們在管 理溫室氣體排放、廢物、電力、燃料及用水方面的路線圖中所概述的 目標。 經營表現 在疫情相關限制放寬後，香港復常，經濟回暖，因此，本集團的非專 利藥業務於報告期內呈增長勢頭。有關增長由社會活動增加及就診人 數回升所推動。 此外，鎮痛藥及抗組胺藥等治療分部亦表現出強勁的增長率，而細胞 毒性化療類別中的三氧化二砷口服液（Arseni ...

企業管治守則的守則條文第C.2.1條 規 定 主 席 與 行 政 總 裁 的 角 色 應 有 區 分，並 不 應 由 一 人 同 時 兼 任。主 席 與 行 政 總 裁 之 間 職 責 的 分 工 應 清 楚 界 定，並 以 書 面 形 式 列 載。 進行證券交易的標準守則 購 買、出 售 或 贖 回 上 市 證 券 審核委員會及本公司管理層亦已審閱截至二零二三年九月三十日止六個月的 中 期 業 績。 暫停辦理股東登記手續 | --- | --- | --- | --- | |-------|-------|-------|------------------------| | | | | | | | | | 承董事會命 | | | | | 雅各臣科研製藥有限公司 | | | | | 執行董事 | | | | | 嚴振亮 | 詞 彙 – 38 – 「健 倍 苗 苗 股 份」 指 健 倍 苗 苗 股 本 中 每 股 面 值0.01港元的普通股 「主 板」 指 聯 交 所 主 板 「私 營 界 別」 指 非 公 營 界 別 「研 發」 指 研 究 及 開 發 「聯 交 所」 指 香 港 聯 合 交 易 所 有 限 ...

Financial Performance - Total revenue for the fiscal year 2023 reached HKD 1,785,579,000, an increase of 11.9% compared to HKD 1,595,543,000 in the previous year[10] - Non-patent drug revenue grew by 6.4% to HKD 1,267,598,000 from HKD 1,191,360,000[10] - Brand healthcare product revenue surged by 28.2% to HKD 517,981,000 from HKD 404,183,000[10] - Gross profit increased by 20.4% to HKD 747,172,000, with a gross margin of 41.8%, up from 38.9%[10] - Profit attributable to equity holders rose by 41.3% to HKD 251,044,000, with a profit margin of 14.1%, compared to 11.1% in the previous year[10] - Adjusted EBITDA for the year was HKD 568,172,000, reflecting a growth of 28.7% from HKD 441,614,000[10] - The adjusted EBITDA margin improved to 31.8% from 27.7%[10] - Adjusted EBITDA for the fiscal year 2023 reached HKD 500,000,000, showing significant growth compared to previous years[22] - Profit attributable to equity holders for fiscal year 2023 was HKD 250,000,000, reflecting a positive trend[23] - The adjusted EBITDA grew by 28.7%, with the gross profit margin rising from 38.9% to 41.8%[53] - The company reported a total revenue of HKD 1,785.6 million for the fiscal year 2023, representing a 12% increase from HKD 1,595.5 million in the previous year[97] - Yearly profit surged by HKD 95.5 million or 50.9% to HKD 283.2 million, reflecting increased operating profit due to the gradual easing of social distancing and travel restrictions[121] Market and Product Development - The company is focusing on expanding its product pipeline, including the development of new specialty drugs and biosimilars to capture fast-growing markets[2] - The company aims to enhance its R&D capabilities and commercial networks to address unmet medical needs[14] - The company is actively exploring partnerships with local and overseas R&D institutions to develop innovative drug manufacturing technologies[2] - The company aims to enhance its R&D capabilities to develop more affordable complex generics, improving access to essential medicines[20] - The company is focusing on developing chronic disease and high-growth treatment areas to provide affordable healthcare solutions[44] - The company launched 22 new products during the reporting period, including Entecavir Tablet and Olmesartan Tablets[42] - The company plans to introduce a new oral anticoagulant and a novel echinocandin for treating invasive fungal infections, enhancing its product portfolio[89] - The company has successfully obtained exclusive licensing agreements for 53 high-efficiency specialty drugs across various therapeutic areas, including oncology and cardiovascular care[66] Operational Efficiency - Cash generated from operating activities was approximately HKD 677.7 million, supporting capacity-building investments and a proposed final dividend of HKD 0.0238 per share, a 33.5% increase from the previous year[53] - The production of liquid formulations increased by 43.1% to approximately 2 million liters, showcasing the company's ability to respond effectively to market needs[45] - The production of eye drop products grew by 18.1%, reaching over 48,000 liters, while solid oral dosage forms increased by 12.0%, totaling over 3.3 billion capsules and tablets[46] - The company is expanding production capabilities to meet growing market demand, focusing on modernizing equipment and optimizing processes[85] - The company has made significant progress in market access in the Greater Bay Area through strategic collaboration with the Hong Kong University Shenzhen Hospital[87] Financial Position - Total assets increased by 13.1% to HKD 5,380,499,000 as of March 31, 2023[26] - Total liabilities rose by 18.2% to HKD 2,123,977,000 as of March 31, 2023[26] - Total equity grew by 10.1% to HKD 3,256,522,000 as of March 31, 2023[26] - The company reported a cash balance of HKD 1,036.4 million at the end of the reporting period, maintaining a robust cash position[62] - The group's net capital debt ratio decreased from 29.2% as of March 31, 2022, to 15.6% as of March 31, 2023, primarily due to a net cash inflow from operating activities of HKD 677.7 million during the reporting period[141] - Bank loans increased by HKD 202.1 million or 15.1%, primarily due to the acquisition of a syndicated loan for refinancing existing floating-rate bank loans[126] Corporate Governance - The board consists of seven directors, including three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced composition[149] - The company has complied with all corporate governance code provisions during the reporting period, except for the separation of the roles of chairman and CEO, which is detailed in the report[146] - The board has established an independence assessment mechanism to ensure strong independent elements, allowing for effective independent judgment[140] - The board is committed to maintaining high standards of corporate governance and has adopted most best practices outlined in the corporate governance code[145] - The company has implemented a written guideline for employees regarding securities trading to ensure compliance with standards[147] Strategic Initiatives - The company has begun supplying a specialized drug to patients at the Hong Kong University Shenzhen Hospital after obtaining regulatory approval, with plans to expand coverage to 14 additional hospitals in the Greater Bay Area[68] - The launch of the e-Jacob Pharma2U digital platform is set for the second half of the year, aimed at enhancing customer service through digital transformation[69] - The company has entered into a strategic partnership with the University of Hong Kong-Shenzhen Hospital to expand into the Greater Bay Area market, which has shown a GDP growth of approximately 7.0% annually over the past decade[93] Employee and Operational Growth - The total number of employees increased to 1,789 as of March 31, 2023, up from 1,736 the previous year, indicating strategic business development and expansion[95] - Employee costs increased by HKD 47.3 million or 11.1%, reflecting the growth in production staff and salary adjustments to support sales growth[102]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責,對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明,並 明 確 表 示,概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 (於開曼群島註冊成立的有限公司) (股份代號:2633) 截至二零二三年三月三十一日止年度的 年度業績公告 財務摘要 • 截至二零二三年三月三十一日止財政年度的收益約為1,785.6百 萬 港 元, 較二零二二年同期約1,595.5百萬港元增加約11.9%。 • 同個財政年度經營溢利約為410.8百 萬 港 元,較 二 零 二 二 年 同 期 約260.9 百萬港元增加約57.5%。 • 年內溢利約為283.2百 萬 港 元,較 二 零 二 二 年 同 期 約187.7百萬港元增加 約50.9%。 • 董事會建議派付截至二零二三年三月三十一日止年度的末期股息每股 普通股2.38港 仙,總 額 約 ...

成 為 你 值 得 信 賴 的 健 康 夥 伴 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號:2633 Pharma Corporation 二二年中期報告 目錄 2 公司資料 24 致董事會的審閱報告 25 未經審核綜合損益及其他全面收益表 3 財務摘要 26 未經審核綜合財務狀況表 27 未經審核綜合權益變動表 4 企業願景及使命 5 公司簡介 28 未經審核簡明綜合現金流量表 29 未經審核中期財務報告附註 6 管理層討論及分析 18 其他資料 43 詞彙 | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------- ...